Hydrophobin-coated echogenic microbubbles as stable and programmable contrast agents
Hydrophobin-coated echogenic microbubbles address the stability and specificity issues of current ultrasound contrast agents by using a hydrophobin and fusion protein mixture for targeted cancer imaging, achieving improved stability and specificity for early-stage cancer detection.
Patent Information
- Application Number
- PCT/FI2024/050221
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-08
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-14
AI Technical Summary
Current ultrasound contrast agents for molecular imaging, such as microbubbles, face challenges in stability and specificity, particularly under high pressure and in targeting specific molecular abnormalities like cancer biomarkers, leading to limited early-stage disease detection capabilities.
Hydrophobin-coated echogenic microbubbles, specifically using a mixture of native type HFBI hydrophobin and HFBI-domZ fusion protein, create a stable and programmable shell that can be decorated with monoclonal antibodies for targeted ultrasound imaging, enhancing stability and specificity to cancer cells.
The hydrophobin-coated microbubbles demonstrate improved stability under high pressure and specific binding to cancer cells, enabling effective early-stage cancer detection and molecular imaging with enhanced echogenicity and programmability.
Smart Images

Figure IMGF000011_0001 
Figure 00000029_0000 
Figure 00000029_0001
Abstract
Description
Hydrophobin-coated echogenic microbubbles as stable and programmable contrast agentsFIELDThis invention relates to the interfacial mechanics of highly stable protein-coated bubbles, especially used as contrast agents for non-invasive ultrasound imaging.BACKGROUNDUltrasound imaging is a widely used diagnostic method and its use is rapidly increased during the last few decades due to several advantages such as its safety, portability, real-time imaging capability, and cost-efficiency. Basically, ultrasound imagining is based on exposing a body to high-frequency sound waves, which are reflected at different interfaces. By calculating the reflected wave (echo) propagating time and the amplitude, an image can be generated.To create a clear image using ultrasound, there should be distinct mechanical variations between tissues of the body parts under investigation. This could be achieved using ultrasound-enhanced contrast agents (UECA). These are substances with predesigned mechanical properties, mainly micro / nanobubbles. UECA can be divided into two main categories, non-targeted and targeted contrast agents. Non-targeted contract agents are bubbles that consist of a non-polar gas core and a shell, which is an amphiphilic membrane of lipids, proteins, or polymers. On the other hand, the targeted ones additionally have a shell that is functionalized and capable of recognizing specific markers on the cell surface, e.g., of infected disease cells, and bonding to them. There are two main procedures to functionalize the shell of the bubble, by embedding the targeting ligands in the main structure of the shell or by decorating the shell with the ligands using covalent or non-covalent interactions.The most extensively tested targeting process is through avidin-biotin interaction. Overconsumption of biotin results in misdiagnosis caused by a significant interference in immunoassays. As a result, this targeting process did not progress beyond the preclinical research stage. Also, other functionalizing processes that do not use avidin have been developed, that apply different conjugation chemistries like maleimide-thiol chemistry.Hydrophobin protein as a stabilizer of non-targeted echogenic microbubbles for ultrasound imaging has been recently reported. Our invention deals with the use of hydrophobin fusion proteins for targeted echogenic microbubbles for molecular imaging.Hydrophobin proteins are a group of highly surface-active, Janus particle-like proteins produced by filamentous fungi. They are relatively small proteins; their size varies between 7 and 15 kDa. Due to their non-centrosymmetric amphiphilic nature Hydrophobins tend to self-organize into a monolayer at any hydrophilic / hydrophobic interface.A mixture of native type HFBI hydrophobin and HFBI-domZ fusion protein is used to create novel echogenic microbubbles as an example of the present invention. This mixture creates a bifunctional layer at the interface of perfluoro-n-butane (C4F10) gas. The bubbles can be decorated with IgG monoclonal antibody molecules that can attach to specific antigens at the targeted surface.SUMMARYThe invention is defined by the features of the independent claims. Some specific embodiments are defined in the dependent claims.According to a first aspect of the present invention, there is provided a protein- coated gas vesicle comprising a fusion protein comprising class II type hydrophobin HFBI.According to a second aspect of the present invention, there is provided a protein- coated gas vesicle comprising a fusion protein comprising class II type hydrophobin HFBI for use in medical applications.According to a third aspect of the present invention, there is provided an ultrasound contrast agent comprising a plurality of gas vesicles comprising a fusion protein comprising class II type hydrophobin HFBI.According to a fourth aspect of the present invention, there is provided a use of the protein-coated gas vesicle comprising a surface layer containing a fusion protein comprising class II type hydrophobin HFBI as an ultrasound contrast agent.BRIEF DESCRIPTION OF THE DRAWINGSFigure 1 shows a schematic illustration of an ultrasound contrast agent and its action in tissue. A) shows the structure of non-targeting and targeting echogenic microbubbles. B) shows the echogenic microbubbles, decorated with specific antibody molecules, attaching to the antigen on the surface of cancer cells.Figure 2 shows a surface activity of HFBI-domZ and size distribution of bubbles. A) shows the surface activity of the hydrophobin fusion protein (HFBI-domZ). The inset shows the measurement setup. B) shows the size distributions of the bubbles, and the inset is an optical microscope image.Figure 3 shows bubbles stability under pressure. A) shows the cross-sectional area changes as the pressure increases in 50 mbar increments up to 200 mbar. B) shows the percentage change in the bubble cross- section area at different pressures. C) shows optical microscope images of a bubble at four different pressures. D) shows the bubble’s response to radical stress changes.Figure 4. Confocal microscopy images and cryo-TEM images, showing the decoration of bubbles by antibody molecules. A) shows a bubble of native-type hydrophobin (HFBI) after adding fluorescent IgG (IgG-NHS-Fluorescein). B) shows a bubble stabilized with 20% HFBI-domZ and 80% HFBI after adding fluorescent IgG. C) shows a bubble of 50% HFBI-domZ and 50% HFBI after adding fluorescent IgG. The insets images in A), B), and C) are the optical images of the same bubbles in transmission mode. D) shows the fluorescence intensity of the bubbles. E) is a cryo-TEM image of a nanobubble of HFBI. F) is a cryo-TEM image of 20% HFBI-domZ + 80% HFBI mixture proteins bubble. G) is the cryo-TEM image of the mixture of 20% HFBI-domZ + 80% HFBI after decoration with IgG.Figure 5. The attachment of bubbles to the cancer cells (in vitro test). A) shows bright-field microscopy images of healthy cells (NIH3T3). B) shows the cancer cells (CT26). While for the healthy cells, only a few bubbles are attached to the cells, there are significantly more bubbles attached to cancer cells. The inset images are 100 x 100 pm areas highlighting bubbles attached to the surface of cells.Figure 6. Bubbles echogenicity. A) An imaging of echogenic microbubbles shows side a wall-less tube containing a buffer solution before bubble injection. B) shows the echogenic bubbles inside the same tube.EMBODIMENTSCancer is a leading cause of global death today, with about 10 million deaths in 2020, according to the World Health Organization (WHO). Early detection of cases is the most effective way to reduce mortality. Traditional diagnostic methods are based on detecting organ dysfunction, which generally occurs at advanced stages of the disease. However, the first sign of disease initiation appears much earlier as molecular abnormalities. We report an advanced design of microbubbles as a molecular probe (targeted microbubbles) that can recognize molecular abnormalities and assist in collecting data on early-stage cancer. This probe consists of a perfluorocarbon gas bubble encapsulated in a functional and stable shell made of a surface-active protein produced by filamentous fungi (hydrophobin HFBI from Trichoderma reesei) and a fusion protein (HFBI-domZ) on which antibodies can be easily grafted. The probe is investigated, among others, using cryo-TEM, confocal microscopy, and in-vitro experiments. The results show the possibility of using this probe as a targeting contrast agent in ultrasound molecular imaging for cancer diagnostics.Medical imaging is an essential part of routine health care. It is used as an important diagnostic tool for disease detection and control. Modern medical imaging comprises techniques such as X-ray, positron emission tomography (PET), magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound imaging.!11These modalities share the same philosophy; they are based on detecting abnormalities in the structure or physiology of organs. These dysfunctions indicate an advanced stage of the disease, while the initial stages of the disease show much earlier signals at the molecular scale. Even though there are some blood tests like complete blood count, it is also based on abnormal changes in the blood, which seems to be a late stage of the development of the disease. This means that current medical imaging does not capture a significant period of disease development, which is crucial for early disease control and treatment.Biomedical research focuses on modalities enabling the visualization, characterization, and quantification of biological behavior at the cellular and subcellular scales, called molecular imaging (Ml). It describes molecular and cellular interactions and disease mechanisms in a living body.[2^]Typically, Ml is applied to establish the basis of a disease by studying molecular abnormalities in cells. It combines one or two conventional medical imaging modalities with a predesigned advanced probe. These probes are agents that consist of two main parts that are linked together. The first part is the signaling source, while the second is the moiety.151For instance, the signal parts are magnetic nanoparticles for MRI, bioluminescent and fluorescent molecules for optical microscopy, or nano- microbubbles for ultrasound imaging.136-81On the other hand, antibodies, viruses, proteins, and small molecules can serve as moiety parts (which can attach to the antigens), which recognize and attach to the target on the surface of abnormal cells.151In addition to these crucial structural parts, the Ml probe requires more features, including high binding affinity and specificity to the target, high sensitivity, high imaging contrast, as well as production and economic feasibility.!41The limitations of Ml techniques that produce high-quality images, like PET / CT and PET / MRI, are that they are expensive and are based on radioactive materials.191In contrast to the radioactive techniques, the ultrasound technique is safer and more cost-effective.Ultrasound imaging is the second most commonly used method after X-ray in medical imaging.1101It exposes the body to high-frequency sound waves reflected at different interfaces. Subsequently, an image is generated by calculating the time elapsed for the ultrasound wave to leave and return to the transducer and its amplitude.13’11-131Generally, the signal part of the ultrasound molecular imaging probe consists of substances that can reflect ultrasound waves stronger than surrounding tissues called contrast agents, like nano-micro bubbles or liposomes.114 151Currently, microbubbles are already used as contrast agents for non-targeted ultrasound imaging, for instance, in heart, liver, and kidney disease diagnoses.1161Microbubbles can be injected intravenously to enhance the contrast due to their viscoelastic properties that cause a stronger reflection of the incident ultrasound wave than the wave reflected from the tissue. They are usually made of a nonpolar gas core (to improve the stability in an aqueous medium) and an interfacial shelltypically made of phospholipids, proteins, or polymers to create a viscoelastic layer that stabilizes the gas core and reflect ultrasound waves.117’181The gas body of the bubbles is normally exhaled via the lungs. The materials of the shell are metabolized by the body, removed by the liver, or filtered by the kidney.1191Commercially available nontargeted microbubbles like Definity® (Lantheus™, United States), Lumason® (Bracco, Italy), Optison™ (GE health care, United States), and Sonazoid™ (Daiichi-Sankyo, Japan) are generally made of phospholipids or albumin protein. At the same time, nanobubbles and liposomes are still in the research stage due to echogenicity (ultrasound wave reflection) and stability challenges.!201Phospholipid-based microbubbles have excellent echogenicity considering their shell viscoelastic properties.1211Although, they present a short lifetime under relatively high pressure inside the blood vessels (around 130 mbar). In contrast, polymer-based microbubbles showed a long lifetime and weak echogenic signal due to the rigidity of their shells.1221However, Jie Cen et al. recently reported an improvement in the signal and the stability of the copolypeptide based contrast agent.1231On the other hand, bubbles based on surface-active proteins have viscoelastic properties between phospholipids and polymers, making them a better alternative for ultrasound contrast agent applications that require high stability for a sufficient period to complete the diagnostic process (between 5 and 15 minutes, depending on the nature of the contrast agent).124 251Our previous work studied the mechanical properties of a unique surface-active protein HFBI, which belongs to the highly surface-active fungal protein family (Class II hydrophobins).1261Hydrophobins are relatively small, Janus-particle-like proteins produced by filaments fungi.1271Due to their amphiphilic nature, they tend to self-organize into a monolayer at various interfaces. They have eight highly conserved cysteine residues forming four disulfide bonds (S-S).128291These bonds cause high stability at interfaces and rigid biological nanoparticle-like behavior.1301The study showed that the mechanical properties of HFBI protein encapsulated gas bubbles are suitable for ultrasound contrast agent application. Hydrophobins can be fused with other functional elements such as second proteins, enzymes, or other functional ligands to get a multifunctional complex.131-341For instance, the HFBI-Protein A fusion protein combines HFBI protein and Protein A fromStaphylococcus aureus.
[3536] This fusion protein is bifunctional because it can create a monolayer at the liquid-gas interface, providing versatile binding and releasing Immunoglobulin G (IgG) antibody molecules.
[0032] Protein A consists of five domains, each capable of binding an IgG molecule physiochemically, providing a straightforward way to functionalize the bubbles by targeting IgG antibodies.Cancerous cells have specific biomarkers (antigens), which are external or internal substances, like proteins, peptides, lipids, polysaccharides, or nucleic acids that can trigger the immune system and can bind to T-cells receptors or specific antibodies. Antibodies can recognize antigens via specific surface features called epitopes, which particular antibody paratopes can identify.Current study focuses on producing a complete design for an ultrasound molecular imaging probe based on surface-active hydrophobin proteins (HFBI and its fusion protein HFBI-domZ).Accordingly, the present invention is directed to a protein-coated gas vesicle comprising a fusion protein comprising class II type hydrophobin HFBI.In a preferred embodiment, protein-coated gas vesicle comprises at least i) class II type hydrophobin HFBI and ii) a fusion protein comprising class II type hydrophobin HFBI.In a preferred embodiment, protein-coated gas vesicle comprises at least i) a phospholipid and / or polyethylene glycol (PEG) and ii) said fusion protein comprising class II type hydrophobin HFBI.In a preferred embodiment, said class II type hydrophobin HFBI is a 7.5 kDa protein originating from Trichoderma reesei.In a preferred embodiment, the present invention is directed to a protein-coated gas vesicle comprising a surface layer (i.e., a shell) containing a fusion protein comprising class II type hydrophobin HFBI and preferably native class II type hydrophobin HFBI.In another preferred embodiment, said fusion protein comprises a domain whereto an antigen binding moiety can be attached.In another preferred embodiment, said antigen binding moiety is selected from the group consisting of: proteins including antibodies, viruses, and small molecules, which can attach to an antigen.In another preferred embodiment, said domain in said fusion protein is from protein A of Staphylococcus aureus.In another preferred embodiment, said domain from protein A is DomZ.In another preferred embodiment, an antibody is attached to said DomZ.In another preferred embodiment, said gas vesicle is formed by a mechanical agitation method. In an alternative embodiment, said gas vesicle is formed by using microfluidics.In a preferred embodiment, said gas vesicle is filled with perfluoro-n-butane gas (C4F10) or SFe. In an alternative embodiment, said gas vesicle is filled with any fluoro-containing gas. In further alternative embodiments, said gas vesicle is filled with a gas selected from the group consisting of: N2, Ar, Ne, C2F6, CF4, C4H10, C3H8, C2H6, CH4, SF6, C3F8, C4F10, CF3H, CF2H2, CFH3, C2F4H2, C2F5H, C3F7H, C3F6H2, C3F5H3, C3F4H4, C3F3H5, and mixtures thereof.In another preferred embodiment, stability of said gas vesicle is based on the adsorption of the HFBI proteins at the liquid / gas interface of said gas vesicle.In another preferred embodiment, the HFBI proteins form a monolayer.In another preferred embodiment, the HFBI proteins provide an amphiphilic shell around the gas vesicle.In another preferred embodiment, the size (i.e., diameter) of said gas vesicle is in the range of 10 nm to 10 pm. In a more preferred embodiment, the size / diameter of said gas vesicle is in the range of10 nm to 100 nm. In another more preferred embodiment, the size / diameter of said gas vesicle is in the range of 2 pm to 10 pm.The present invention is also directed to a protein-coated gas vesicle as defined herein for use in medical applications including drug delivery. In an alternative embodiment, the present invention is directed to a protein-coated gas vesicle as defined herein for use as a medicine.In a preferred embodiment, the protein-coated gas vesicle for said use is to be administered intravenously.It is also notable that it would be obvious for a person skilled in the art reading this disclosure that the protein-coated gas vesicle as defined herein has many other uses in medical diagnostics, delivery of therapeutics, and delivery of theranostics.The present invention is also directed to an ultrasound contrast agent comprising a plurality of the protein-coated gas vesicles as defined herein.In a preferred embodiment, said ultrasound contrast agent is for intravenous administration.The present invention is also directed to a use of the protein-coated gas vesicle of the present invention as an ultrasound contrast agent.In an embodiment, a mixture of HFBI and HFBI-domZ fusion protein, consisting of one HFBI molecule and one functional domain from protein A, is used to design echogenic microbubbles. This mixture of molecules self-assembles into a bifunctional layer at the interface between perfluoro-n-butane (C4F10) gas and phosphate-buffered saline (PBS), in which the microbubbles are dispersed. The bubbles containing domZ moieties are then functionalized with monoclonal antibody molecules that can bind to specific antigens on the surface of targeted cells. This allowed us to decorate our bubbles with the desired antibody for known target epitopes. The bubbles presented here are echogenic and programmable molecular targeting agents.In the present description, the terms “microbubble”, “bubble” and “gas vesicle” as used herein can all refer to the highly stable protein-coated structures of the present disclosure.The verbs “to comprise” and “to include” are used in this document as open limitations that neither exclude nor require the existence of also un-recited features. The features recited in depending claims are mutually freely combinable unless otherwise explicitly stated. Furthermore, it is to be understood that the use of "a" or "an", i.e. a singular form, throughout this document does not exclude a plurality.While the forgoing examples are illustrative of the principles of the present invention in one or more particular applications, it will be apparent to those of ordinary skill in the art that numerous modifications in form, usage and details of implementation can be made without the exercise of inventive faculty, and without departing from the principles and concepts of the invention. Accordingly, it is not intended that the invention be limited, except as by the claims set forth below.EXPERIMENTAL SECTIONMaterials. Perfluoro-n-butane 98% was purchased from ABCR (Karlsruhe, Germany). NHS-Fluorescein antibody labeling kit was obtained from Thermo Fisher Scientific. IgG antibodies, POHG, and PBS were purchased from Sigma- Aldrich (Missouri, USA). Water was deionized using a Milli-Q water purification system (Millipore) with a resistivity of around 18.2 MQ cm. Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco), antibiotics (10,000 pg / mL streptomycin and 100,000 U / mL penicillin, Gibco), and fetal bovine serum (FBS, Gibco) were purchased from Fisher Scientific. Fibronectin was purchased from Sigma-Aldrich.Protein expression and purification. HFBI hydrophobin protein is produced and purified as described in Linder et a / .
[0042] In this work, a coated copper gridBL21 star(DE3) (Invitrogen) E. coli strain carrying pMJS205 plasmid for codon- optimized S. cerevisiae Erv1 + codon-optimized human PDI[431was used to express HFBI-DomZ protein from plasmid pHZ001 simultaneously. The plasmid pHZ001 is based on the pET28b+ expression vector. The expression vector carried a codon-optimized version of the HFBI-DomZ encoding gene cloned between Ncol and Hind 111 sites of pET28b+, thus adding a Hexa histidine tag in the C-terminus of the HFBI-DomZ fusion protein. The HFBI-DomZ fusion consisted of Trichoderma reesei hydrophobin I (HFBI)[341and a Modified version of Staphylococcus aureus protein A B-domain B, called Z-domain (DomZ)[361.Amino acid sequence (SEQ ID NO:1 ) of the prepared HFBI-DomZ fusion protein is:For protein HFBI-DomZ expression, E. coli strain B7405 was cultured in a modified ZYM medium with 0.35% glucose at 37 °C at 220 rpm for the shake flask culture that was used as an inoculum.[441The final culture step was done in a 15-liter volume in a stainless-steel fermenter vessel (Braun Biostat) in ZYM modified with 0.05% glucose at 37 °C, pH 6.8. The cultivation time was 20 hours.The cells were simultaneously lysed and purified by aqueous two-phase separation. First, the culture medium was supplemented with 137 mM NaCI, 10 mM Na2HPO4, 2.7 mM KCI, 1.8 mM H2PO4, 4% Triton X-114, 10 mM PMSF, 10 mM EDTA and incubated overnight at room temperature under gentle shaking (80 rpm). To trigger the phase separation, the mixture was centrifuged for 20 min at 10,000 g. Next, the lower phase was collected and washed with an equal volume of isobutanol to extract the hydrophobin fusion proteins and centrifuged again. Finally, the aqueous phase was collected and stored at -20 °C prior to further purification. The final purification step was done by immobilized metal affinity chromatography with a Fast Flow Chelating Sepharose column (GE) at pH 7.5 following the manufacturer’s protocol. DG-10 gel filtration columns (Bio-Rad) were used to exchange the buffer with PBS (137 mM NaCI, 10 mM Na2HPO4, 2.7 mM KCI, 1.8 mM H2PO4). Finally, protein purity was assessed on SDS PAGE, and the concentration was determined with a spectrophotometer by measuring absorbance at 280 nm. The theoretical pl and Mw of HFBI-domZ are 6.35 and 16645.62 kDa, respectively.Bubbles formation. 1 ml of 0.2 mg / ml solution consisted of 80% HFBI hydrophobin protein and 20% HFBI-domZ fusion protein in PBS placed inside a 2.5 ml glass vial. The vial was sealed using an aluminum cap and a septum. The air inside the vail was replaced with C4F using a 50 ml Hamilton syringe. The vial was placed in a VialMix shaker and agitated for 45 s. A white suspension composed of nano and microbubbles was obtained.Surface tension and surface dilatational rheology. Static surface tension and mechanical properties of the HFBI-domZ layer adsorbed at three non-polar gases (air, C4F , and SFe) interfaces were carried out using an optical tensiometer (Theta tensiometer, Biolin Scientific, Finland). The obtained data were analyzed using OneAttension software (Biolin Scientific). First, a hooked needle filled withone of these gases using a Hamilton syringe was immersed in a solution of HFBI- domZ fusion protein (0.01 mg / ml). Then, a 10 pl gas bubble was created at the tip of the needle. The bubble was monitored for about 3 h to measure the static surface tension, employing the axisymmetric drop shape analysis. When the curvature of the surface tension reached a steady state, a sinusoidal volume disruption was applied using an integrated pulsated droplet module (PD-200). The change in bubble volume was monitored for 40 s, and the loss and storage moduli were collected using the same software (One Attention, Figure 1A-C).Bubble size distribution. Bubble size distribution was measured by laser diffraction using the Mastersizer 2000 (Malvern Panalytical, UK). Each sample was measured at least thrice, with three runs in each measurement. The stirrer speed was 2000 rpm. Refractive indexes of 1 and 1 .33 were used for the dispersed phase (air) and dispersant (water), respectively. A volume-based distribution was obtained.Zeta potential (ZP). The bubbles’ ZP was measured using a Malvern Zetasizer Nano ZS90 (Malvern Panalytical, UK) based on the electrophoretic mobility principle. Samples were measured in a micro cuvette using a dip cell with an equilibration time of 2 min at 25 °C. Three runs of at least 30 continuous readings were obtained for each sample. Smoluchowski equation was used for ZP calculation.Confocal microscopy. Three batches of protein solutions consisting of 100% native-type HFBI, 80% HFBI + 20% HFBI-domZ, and 50% HFBI + 50% HFBI- domZ were prepared to create microbubbles (as explained in the formation of bubbles section). The antibody molecules labeling procedure was executed according to the protocol in the labeling kit. Bubble solutions were diluted in 40 ml of distilled water and centrifuged for 1 min at 48 RCF. Then, 5 ml from the top of the supernatant were mixed with 10 pl of IgG-NHS-Fluorescein (2 mg / ml), and the mixture was incubated for 20 min at room temperature, protected from light. After that, the mixture was diluted in 40 ml of distilled water and centrifuged for 1 minute at 48 RCF. The supernatant of solution was collected and used for the confocal microscopy experiments. The samples observed by confocal microscopy arecapillaries filled by the capillary effect by immersing them in the top of the supernatant.Bubbles in the capillaries have been observed by confocal microscopy (LSM 710 from Zeiss, Germany). Experiments were performed with ex = 488 nm and Aem = 490 - 753 nm. The same parameters were used for each sample to compare signal intensities.Atomic force microscopy. A 100 pl droplet made of a mixture of HFBI native-type protein (0.2 mg / ml) and HFBI-domZ (0.2 mg / ml) fusion protein mixtures was placed on a parafilm substrate for about 1 h to get a flattened area on top of the droplets and to ensure that we have a monolayer at the interface. Then, a highly ordered pyrolytic graphite (HOPG, ZYA quality) substrate was brought into contact with the top of the droplets. The substrate with a hydrophobin monolayer was gently washed with 200 ml of distilled water. The sample was placed on the AFM stage for about 30 min before use to ensure that the sample was dehydrated.AFM measurements were carried out using a Dimension Icon AFM (Bruker AXS, France; formerly Veeco) with a ScanAsyst-air cantilever (sharp silicon nitride tip with a nominal radius of 2 nm for PeakForce Tapping in the air). The scan size was set to 100 nm x 100 nm with a 256 x 256 pixels resolution, and the scan was done at a frequency of 1 kHz. The ScanAsyst Auto control was set to “individual” with a PeakForce Amplitude of 170 nm. The spring constant and PeakForce frequencies were 0.4 N / m and 2 kHz for all samples. Individual scans were performed for each sample at multiple locations on the surface.Cryo-TEM. 5 pl droplets of nanobubble dispersions were deposited on a lacey carbon treated with plasma (Electron Microscopy Sciences). Droplets were blotted with filter paper, plunged into liquid ethane (-170 °C) using an automatic plunger freezer (EM GP2, Leica), and stored in liquid nitrogen. The samples were visualized using a JEM-3200FSC (JEOL) microscope at 300 kV acceleration voltage, and images were acquired using Digital Micrograph software (Gatan).Pressure experiments. Microfluidic devices were prepared by UV-curing a rectangular glass capillary (CM Scientific, 0.2 x 2.0 x 50 mm) on a microscopy slide and a needle (25Gx5 / 8”) on one side of the capillary. The needle was then connected to a reservoir via PTFE tubing (ID ~ 250 pm). The reservoir was filledwith PBS and connected to a piezoelectric controller unit (Elveflow). The tubing and the capillary were filled with PBS, then a droplet of bubbles was deposited on the other side of the capillary (the side not connected to the tubing) and carefully aspired in the capillary. After the bubbles had been aspirated, the capillary was sealed using a thermosensitive wax (PELCO Quickstick 135).The desired pressures were applied using the pressure controller software (ESI). Experiments were observed with an inverted microscope (Nikon Eclipse Ti), and bright-field images of the bubbles were recorded with an sCMOS camera (Zyla- 4.2-CL10, Andor) operated using pManager (2.0 beta) open-source microscopy software. Images were exported and analyzed using Imaged.Cell experiments. Noncancerous murine fibroblast NIH3T3 cells and mouse colon carcinoma CT26 cells (ATCC CRL-2638; American Tissue Culture Collection) were used in the study. Cells were cultured at 37 °C under a 95% air / 5% CO2 atmosphere in culture medium consisting of DMEM supplemented with 10% (v / v) FBS and antibiotics (100 pg / mL streptomycin and 100 U / mL penicillin).Observation chambers were prepared as follows. Circular 25-mm cover glasses were sonicated in ethanol for 5 min, dried at room temperature, and plasma- cleaned (Henniker plasma HPT-100) for 10 min. The cover glasses were coated with a 0.1 mg / l solution of fibronectin (Sigma-Aldrich) in PBS for 1 h.The observation chambers were filled with DMEM containing either NIH3T3 cells (with a concentration of 107cells / ml) or CT26 cells (with a concentration of 5 x 106cells / ml). After 1 day of incubation at 37 °C with 5% CO2, the medium was removed from the chambers, the chambers were washed with PBS, and then filled with a bubble solution. The chambers were then closed with a 30-mm cover glass on the upper side, and the magnetic chambers were flipped upside down so that the cells were in contact with the bubbles. The chambers were then placed for 30 min in the incubator, after which the observation chambers were flipped again so that the cells were at the bottom of the observation chambers. Finally, the supernatant was discarded to remove the unattached bubbles, and the cells were observed by bright field microscopy.Tissue mimicking material. Graphite agar phantom was prepared as follow. 3 g of agar were mixed with 150 ml of degassed distilled water. The mixture was heatedto 75 °C on a hot plate with a magnetic stirrer. After that, 4.3 g of graphite were added to the mixture and heated to 95 °C. The mixture was then poured into molds and stored in a cool water bath.[451The echogenicity of the bubbles. The graphite agar phantom that has tube like empty space in the middle with a diameter around 3 mm was placed on a plastic Petri dish. A portable ultrasound imaging device (Clarius Scanner L20 HD, Canada) was maintained in contact with phantom from the top as shown in Figure S4. To avoid any empty space between the phantom and the device, some of ultrasound transmission gel was placed in between. After that, bubbles suspension prepared as described in bubbles formation section was drawn into a syringe and injected inside the phantom and imaged. As a control experiment, we injected a buffer solution (PBS) without any bubbles.Results and discussionUltrasound molecular imaging probe architecture. Native-type HFBI gas bubbles encapsulated in C4F10 can serve as a non-targeting contrast agent (Figure 1A). In addition, a mixture of HFBI and HFBI-domZ fusion protein creates functional bubbles that can be decorated with a specific monoclonal antibody to target a particular antigen on the surface of the cancer cells (Figure 1 B).Surface activity and mechanical properties. Hydrophobins and their fusion proteins, such as HFBI-domZ, are highly surface active due to their amphiphilic nature. Therefore, they adsorb at gas-liquid interfaces as a viscoelastic monolayer. The adsorption rate and mechanical properties of the viscoelastic layer play an essential role in bubble generation and their functional properties. The adsorption rate is affected by the bulk concentration and surface activity of the molecules. The surface activity of the HFBI-domZ fusion protein was investigated using three gases: air (78% N2), perfluoro-n-butane (C4F10), and sulfur hexafluoride (SFe). Air is used as a reference, while C4F10 and SFe are gases of choice for the aimed applications because they are highly hydrophobic and heavier than air in aqueous solutions. The adsorption of the molecules significantly lowers the surface tension, as demonstrated by the sharp slope of the surface tension curve, where its values decreased by more than 20 mN / m (Figure 2A). In addition, the curves almostreach the steady state within 35 minutes, confirming the high affinity of the HFBI- domZ molecules with gas-liquid interfaces.The mechanical properties of the protein layers at the interface were measured using the axisymmetric bubble shape analysis method. Table 1 shows the storage (E’) and loss moduli (E”) of the layers.Table 1. Storage and loss moduliInterface E’ (mN / m) E” (mN / m)Air / water 126 ± 18 18 ± 8SF6 / water 124 ± 7 16 ± 2The storage moduli were almost identical for the layers formed at the air-water and SFe-water interfaces. However, the layer at the C4F -water interface has a slightly higher storage modulus and smaller loss modulus, meaning that the layer dissipates more energy in compression and induces less resistance in expansion. In other words, the layer is more viscoelastic, which makes it the best choice for non-linear ultrasound wave reflection applications. In addition to the mechanical properties of the adsorbed layer, perfluorocarbon gases play a unique role in bubble stability (half-life time). They have an extremely low water solubility (0.021 mol / m3for perfluoro butane), meaning the gas molecules remain inside the bubbles, creating a pressure that balances the surface tension and blood pressure.!181For these reasons, we focus on microbubbles produced with C4F10 in the rest of this work.The typical ultrasound contrast agent bubbles size is between submicron to 8 microns in diameter. They are relatively large (in the range of red blood cells) to ensure better echogenicity and keep them in size so they can travel smoothly in the blood circulatory system.1161We determine the size distribution of the bubbles, as well as the introduction of HFBI-domZ in the monolayer and the functionalization of the bubbles with IgG, by performing dynamic light scattering and zeta potential measurements. We characterize bubbles with three different formulations: i) native-type hydrophobin HFBI, ii) 20% HFBI-domZ fusion protein + 80% HFBI, and iii) 20% HFBI-domZ + 80% HFBI + IgG. The size distribution of the bubbles shows that the peaks of the volume percentage of these formulations are4.5, 6, and 5 micrometers, respectively (Figure 2B). In the case of the bubbles decorated with IgG molecules, there is a second peak in the diagram in the range of 100 microns.The bubbles coated with HFBI have the smallest size and lowest zeta potential (- 66 ± 6). These negatively charged bubbles can easily create a repulsion force between each other and prevent any coagulation. While, in case of HFBI + HFBI- domZ, the average size of the bubbles increases, and the zeta potential is still in the negative side (-54 ± 6). These changes can be interpreted as a piece of indirect evidence for the adsorption of HFBI-domZ molecules at the interface. That result is also confirmed using the AFM imaging technique. On the other hand, the significant change in the zeta potential of the surface of the bubbles decorated with IgG molecules (15 ± 2) can be recognized as indirect proof of the attachment between IgG molecules and the surface of the bubbles since the Zeta potential of IgG is around 15 mV in pH around 5.5, which is the pH value of Mi II i-Q water371With this slightly positive value, the bubbles can be simply attach to each other and create some aggregations. Assuming the aggregation of the bubbles in this condition can explain the second peak in the size distribution curve (Figure 2B, the blue curve). The aggregates of the bubbles with IgG molecules could be solved using filtration or centrifugation for the end applications.Stability of bubbles under high pressure. As mentioned earlier, bubbles must withstand relatively high blood pressure, as well as stretch and compress to reflect non-linear ultrasound echoes. Since normal blood pressure is around 130 mbar, bubbles must survive pressures at least equal to that. HFBI forms a rigid monolayer at gas interfaces. Mixing HFBI with HFBI-domZ makes the layer more elastic, which could affect the stability of the bubbles under high pressure. For percentage ratios up to 30% of HFBI-domZ, HFBI dominates the interface, and there is no good fit between the bubble shape and the software due to the rigid- like behavior of HFBI. On the other hand, at higher HFBI-domZ ratios, such as 40 and 50%, the layer behaves like an elastic layer.A homemade setup was used to measure that bubble stability to ensure bubbles survive in the circulatory system. External pressure was applied to a group of bubbles inside a capillary, and the evolution of their cross-section was monitoredusing an inverted optical microscope. The pressure was increased from 0 to 200 mbar in 50 mbar increments, and each step was maintained for 10 minutes to each a steady state (Figure 3A). The cross-sectional area decreased with each step by 3%, 5%, 13%, and 24%, respectively (Figure 3B and C). This means that even though the pressure was much higher than the normal blood pressure, bubbles shrank by less than 25% of their original size. In addition, when the external pressure returned to 0 mbar, the bubble quickly recovered 80% of its original volume. This means that only 20% of perfluoro-n-butane gas diffused to the bulk solution at 200 mbar pressure.Furthermore, the response of the bubbles to radical pressure changes was observed when the external pressure was periodically alternated between 0 and 130 mbar (Figure 3D). The pressure was switched on and off every 25 seconds for 500 seconds. Therefore, the harmonic response of the bubble size to the pressure changes reflects their elastic properties, which is crucial for non-linear ultrasound echoes. In addition to the high pressure, bubbles respond to the negative pressure, and their cross-sections increase when the pressure decreases, confirming the elasticity of the protein layer.Bubbles decoration with antibody molecules. The main difference between targeting and non-targeting microbubbles is their ability to recognize targeted biomarkers on the surface of abnormal cells. Bubbles decorated with a moiety part like polypeptides, proteins, or antibodies will functionalize bubbles to identify the targeted biomarkers. In an example, the interface of the bubbles consists of HFBI- domZ and HFBI proteins. HFBI-domZ can bind to IgG antibody molecules by recognizing their FC (fragment crystallizable region) part, making the bubble fully covered with antibody molecules that have free Fab (fragment antigen-binding region) parts to recognize and attach to the antigen on the surface of the infected cells. Confocal laser scanning microscopy and cryogenic electron microscopy were used to ensure the decoration of the HFBI + HFBI-domZ-based microbubbles with IgG antibodies.As explained in the experimental section, three batches of bubbles encapsulating perfluoro-n-butane were prepared and investigated. From Figures 4A-D, one can see the significant increase in fluorescence intensity with the percentage increaseof HFBI-domZ, confirming the linear correlation between the number of HFBI- domZ molecules in the structure of the bubble and the attachment of IgG-NHS- Fluorescein molecules. The average fluorescence intensity was around 3600 (arbitrary unit) when bubbles were coated only with HFBI. While in the case where the layer contains 20% and 50% of HFBI-domZ, the fluorescence intensities were 17000 and 48000, respectively. The low fluorescence intensity value in the case of no HFBI-domZ is expected due to the non-selective adsorption of IgG at the bubble's surface. In contrast, the high value is due to the selective attraction between the domZ and the FC part of the IgG.Cryo-TEM also confirms the binding between the domZ and the FC part of the IgG. Nanobubbles from three batches of micro / nanobubbles were investigated due to the cryo-TEM size limitation. The first batch consists of bubbles with a shell of HFBI (Figure 4E). The second batch of bubbles has a shell of 80% HFBI and 20% HFBI-domZ (Figure 4F). The third batch of bubbles has a shell of 80% HFBI and 20% HFBI-domZ functionalized with IgG (Figure 4G). The shell thickness for the HFBI bubbles was around 3.1 nm, corresponding to the length of one HFBI molecule. The HFBI-domZ molecules made the shell a bit thicker, with a thickness of about 3.3 nm. Nevertheless, the shells remained smooth in both cases, as shown in Figures 4E and 4F. On the other hand, Figure 4G confirms the functionalization of the HFBI- domZ with IgG with the observation of a shell with a hairy structure. Indeed, the hairy region is 10 nm thick, which matches the length of one IgG molecule.Antigen recognition and binding to the surface of cancer cells. Finding the desired target (biomarker) on the surface of the cells represents the most challenging part of developing a molecular imaging probe. The critical point in this process is the selective attachment between the antigen on the surface of the cancer cells and the moiety part on the surface of the microbubbles. To assess the selective attachment of our bubbles to a specific antigen, in vitro experiments were performed using a cancer cell line (CT26) having the targeted antigen and compared with a healthy cell line (NIH3T3) as a control. CT26 is a colon carcinoma cell line, and its surface has a biomarker called CD87.[381The CD87 cell surface receptor, which is also known as the Urokinase-type plasminogen activator receptor (uPAR), is expressed at a high level in tumor cells, in contrast tohealthy cells, where it is expressed at a low level.
[0040] To target the CD87 antigen, the microbubbles are decorated with anti-antigen monoclonal antibody molecules lgG1 k. As explained in the experimental part, decorated bubbles were brought into contact with the CT26 and NIH3T3 cells. Figure 5A shows an optical microscope image of a group of NIH3T3 cells (have several CD87 antigens) after incubation and washing steps. The whole image has four bubbles attached, three attached to the surface of cells and one directly to the substrate. The inset image (100 x 100 pm) has only three microbubbles. In contrast with the image shown in Figure 5B, there are hundreds of bubbles attached to the CT26 cells. There are around 115 microbubbles in the inset image (100 x 100 pm). This tends to confirm the selective attachment of the decorated bubbles to the target. In addition, this may lead to the assumption of the programmability of our bubbles, which means that the bubbles could be decorated with any monoclonal anti-antigen to target a specific surface receptor.Echogenicity of the bubbles. As an ultrasound contrast agent, echogenic bubbles are an excellent tool for disease diagnosis. The physical properties of echogenic bubbles enable them to reflect ultrasound waves and thus appear clearly in the space where they are located. Bubbles can be non-targeting, meaning they have no specific affinity to attach to any target, or they can be functionalized with a particular moiety that can recognize and adhere to a target tissue. Bubbles allow the visualization of blood and blood flow within an organ by differentiating between normal and abnormal conditions. Therefore, the quality of the ultrasound image is highly related to the echogenicity of the contrast agent.The echogenicity of our bubbles (the bubbles shell consists of 80% HFBI + 20% HFBI-domZ) was assessed using a portable ultrasound imaging device. Figure 6 shows the bubbles in a wall-less tube inside a tissue-mimicking material consisting of an agar hydrogel containing graphite microparticles. The dark area in the left image corresponds to the tube filled only with PBS before bubbles injection. After injection, we can see a gradient of bubbles in the right image, with the highest concentration at the top of the tube (in white) and the lowest at the bottom (in black). Due to buoyancy, bubbles accumulate at the top, showing a clear difference between the tube and the tissue-mimicking material (right side, Fig. 6A)compared to the image without bubbles (left side, Fig. 6B). The right image shows that even a few bubbles can be seen in the ultrasound image.ConclusionMolecular imaging based on echogenic microbubbles represents an advancement in disease diagnosis. It allows the detection of disease biomarkers at an early stage, which is crucial for their control and treatment. In addition to their primary function as ultrasound contrast agents for diagnostics, bubbles can serve as cargo for oxygen and drug delivery.!401Furthermore, bubbles have the potential to work as a targeting destroyer of infected cells and tissues through ultrasound-induced internal cavitation.1411This study focuses on the main characteristics of a novel advanced ultrasound molecular imaging probe design as a non-invasive and cost-effective diagnostic modality. Ultrasound was combined with echogenic microbubbles to target the biomarker on the surface of mouse colon carcinoma cells. The crucial properties such as size, stability, echogenicity, and biomarker detection have been studied. To reach high stability and good target accessibility, peril uoro-n-butane (C4F10) gas bubbles encapsulated with a mixture of native type HFBI hydrophobin and HFBI-domZ fusion protein were prepared and mainly have a size similar to that of red blood cells (between 7 and 10 pm). The stability of the bubbles under high pressure was tested using a custom-made capillary system connected to an inverted optical microscope. The results confirmed that the bubbles survive under a pressure of 200 mbar, which is much higher than the typical human blood pressure (130 mbar). The bubbles were decorated with two different IgG antibody molecules, and the decoration was confirmed using confocal microscopy and cryo- TEM. This suggests that bubbles can be redesigned to target different antigens.The echogenicity of the bubbles was tested using a portable ultrasound scanner to ensure their ability to serve as a signal part for the ultrasound imaging molecular probe. Finally, the ability of the bubbles to serve as a moiety part for the probe was tested through in vitro experiments. Many bubbles found the targeted antigen on the surface of cancer cells and bound to them, compared to healthy cells, to which a negligible number of bubbles were attached.Based on these results, an advanced ultrasound imaging molecular imaging probe with programmability potential is developed and proposed for further in vivo experiments as an essential step before medical applications.REFERENCES[1] P. Suetens, Fundamentals of Medical Imaging, Cambridge University Press, 2009.[2] R. Weissleder, U. Mahmood, Radiology 2001, 219, 316.[3] G. Kbse, M. Darguzyte, F. Kiessling, Nanomaterials 2020, 10, 1935.[4] J.-B. L. Vishal Thumar John Eisenbrey, Advanced Ultrasound inDiagnosis and Therapy 2019, 3, 62.[5] K. Chen, X. Chen, Curr Top Med Chem 2010, 10, 1227.[6] A. Avasthi, C. Caro, E. Pozo-Torres, M. P. Leal, M. L. Garcia-Martin, Top Curr Chem (Z) 2020, 378, 40.[7] J. Ariztia, K. Solmont, N. P. Moise, S. Specklin, M. P. Heck, S. Lamande-Langle, B. Kuhnast, Bioconjugate Chem. 2022, 33, 24.[8] M. A. Nakatsuka, R. F. Mattrey, S. C. Esener, J. N. Cha, A. P. Goodwin, Advanced Materials 2012, 24, 6010.[9] Z. T. Al-Sharify, T. A. Al-Sharify, N. T. Al-Sharify, H. Yahya naser, IOP Conf. Ser.: Mater. Sci. Eng. 2020, 870, 012043.
[0010] Operational Information for Commissioning, Diagnostic Imaging Dataset Annual Statistical Release 2017 / 18, NHS England, England, Leeds, 2018.
[0011] R. S. Cobbold, Foundations of Biomedical Ultrasound, Oxford University Press, 2006.
[0012] T. L. Szabo, Diagnostic Ultrasound Imaging: Inside Out, Academic Press, 2004.
[0013] Ihnatsenka, Barys, Boezaart, Andre, International Journal of Shoulder Surgery 20 0, 4, 55.
[0014] Villanueva, Flordeliza S, Jankowski, Ron J, Klibanov, Sasha, Pina, Maris L, Alber, Sean M, Watkins, Simon C, Brandenburger, Gary H, Wagner, William R, Circulation 1998, 98, 1.
[0015] S.-L. Huang, A. J. Hamilton, A. Nagaraj, S. D. Tiukinhoy, M. E. Klegerman, D. D. Mcpherson, R. C. Macdonald, Journal of Pharmaceutical Sciences 2001, 90, 1917.
[0016] H. Yusefi, B. Helfield, Frontiers in Physics 2022, 10, DOI 10.3389 / fphy.2022.791145.
[0017] J. G. Riess, Artificial Cells, Blood Substitutes, and Immobilization Biotechnology 2005, 33, 47.
[0018] E. G. Schutt, D. H. Klein, R. M. Mattrey, J. G. Riess, Angewandte Chemie - International Edition 2003, 42, 3218.
[0019] E. Quaia, European Radiology 2007 , 17, 1995.
[0020] N. Hamano, S. Kamoshida, Y. Kikkawa, Y. Yano, T. Kobayashi, Y. Endo-Takahashi, R. Suzuki, K. Maruyama, Y. Ito, M. Nomizu, Y. Negishi, Pharmaceutics 2019, 11, 1.
[0021] P. Frinking, T. Segers, Y. Luan, F. Tranquart, Ultrasound in Medicine and Biology 2020 , 46, 892.
[0022] L. Hoff, P. C. Sontum, J. M. Hovem, The Journal of the Acoustical Society of America 2000, 107, 2272.
[0023] J. Cen, X. Ye, X. Liu, W. Pan, L. Zhang, G. Zhang, N. He, A. Shen, J. Hu, S. Liu, Angewandte Chemie International Edition 2022, 61, e202209610.
[0024] R. Gessner, P. A. Dayton, Mol Imaging 2010, 9, 7290.2010.00022.
[0025] E. H. Chang, Nephron 2018, 138, 176.
[0026] H. H. Al-Terke, G. Beaune, M. Junaid, J. Seitsonen, A. Paananen, J. V. I. Timonen, J. Joensuu, F. Brochard-Wyart, R. H. A. Ras, Proceedings of the National Academy of Sciences 2023, 120, e2211509120.
[0027] J. G. H. Wessels, O. De Vries, S. A. Asgeirsdottir, F. Schuren, The Plant Ce / / 1991, 3, 793.
[0028] HAB. Wosten, OMH. De Vries, JGH. Wessels, The Plant Cell 1993, 5, 1567.
[0029] B. W. Berger, N. D. Sallada, Journal of Biological Engineering 2019, 13, 1.
[0030] S. R. Euston, Food Hydrocolloids 2014, 42, 66.
[0031] L. J. Reuter, M. A. Shahbazi, E. M. Makila, J. J. Salonen, R. Saberianfar, R. Menassa, H. A. Santos, J. J. Joensuu, A. Ritala, Bioconjugate Chemistry 2017 , 28, 1639.
[0032] K. Kurppa, L. J. Reuter, A. Ritala, M. B. Linder, J. J. Joensuu, Plant Biotech nol J 2018, 76, 404.
[0033] A. Paananen, D. Ercili-Cura, M. Saloheimo, R. Lantto, M. B. Linder, Soft Matter 2013, 9, 1612.
[0034] T. Nakari-Setala, N. Arc, N. Kalkkinen, E. Alatalo, M. Penttila, European journal of biochemistry 1996, 235, 248.
[0035] M. Uhlen, B. Guss, B. Nilsson, S. Gatenbeck, L. Philipson, M. Lindberg, Journal of Biological Chemistry 1984, 259, 1695.
[0036] B. Nilsson, T. Moks, B. Jansson, L. Abrahmsen, A. Elmblad, E. Holmgren, C. Henrichson, T. A. Jones, M. Uhlen, Protein Eng Des Sei 1987, 7, 107.
[0037] J. Mathes, W. Friess, European Journal of Pharmaceutics and Biopharmaceutics 2011 , 78, 239.
[0038] D. J. Agorku, A. Langhammer, U. Heider, S. Wild, A. Bosio, O. Hardt, Front Oncol 2019, 9, 716.
[0039] B.-T. Zhai, H. Tian, J. Sun, J.-B. Zou, X.-F. Zhang, J.-X. Cheng, Y.-J. Shi, Y. Fan, D.-Y. Guo, J Transl Med 2022, 20, 135.
[0040] M. S. Khan, J. Hwang, K. Lee, Y. Choi, K. Kim, H. J. Koo, J. W. Hong, J. Choi, Molecules 2018, 23, 1 .
[0041] M. G. Shapiro, P. W. Goodwill, A. Neogy, M. Yin, F. S. Foster, D. V. Schaffer, S. M. Conolly, Nature Nanotech 2014, 9, 311 .
[0042] M. Linder, K. Seiber, T. Nakari-Setala, M. Qiao, M.-R. Kula, M. Penttila, Biomacromolecules 2001, 2, 511 .
[0043] A. G^ciarz, N. K. Khatri, M. L. Velez-Suberbie, M. J. Saaranen, Y. llchida, E. Keshavarz-Moore, L. W. Ruddock, Microbial Cell Factories 2017, 16, 108.
[0044] F. W. Studier, Protein Expression and Purification 2005, 41, 207.
[0045] N. Alves, A. Kim, J. Tan, G. Hwang, T. Javed, B. Neagu, B. K. Courtney, Ultrasound in Medicine & Biology 2020, 46, 2057.
Claims
CLAIMS1 . A protein-coated gas vesicle comprising a fusion protein comprising class II type hydrophobin HFBL2. The protein-coated gas vesicle according to claim 1 , wherein said gas vesicle comprises class II type hydrophobin HFBI and said fusion protein comprising class II type hydrophobin HFBI.
3. The protein-coated gas vesicle according to claim 1 , wherein said gas vesicle comprises a phospholipid and said fusion protein comprising class II type hydrophobin HFBI.
4. The protein-coated gas vesicle according to any one of claims 1-3, wherein said fusion protein comprises a domain whereto an antigen binding moiety can be attached.
5. The protein-coated gas vesicle according to claim 4, wherein said antigen binding moiety is selected from the group consisting of: proteins including antibodies, viruses, and small molecules, which can attach to an antigen.
6. The protein-coated gas vesicle according claim 4 or 5, wherein said domain in said fusion protein is from protein A of Staphylococcus aureus.
7. The protein-coated gas vesicle according to claim 6, wherein said domain from protein A is DomZ.
8. The protein-coated gas vesicle according to claim 7, wherein an antibody is attached to said DomZ.
9. The protein-coated gas vesicle according to any of claims 1 -8, wherein said gas vesicle is filled with perfluoro-n-butane gas (C4F10) or sulfur hexafluoride gas (SFe).
10. A protein-coated gas vesicle according to any one of claims 1-9 for use in medical applications including drug delivery.11 . The protein-coated gas vesicle for use according to claim 10, wherein said gas vesicle is to be administered intravenously.
12. An ultrasound contrast agent comprising a plurality of gas vesicles according to any one of claims 1 -9.
13. The ultrasound contrast agent according to claim 12, wherein said ultrasound contrast agent is for intravenous administration.
14. Use of the protein-coated gas vesicle according to any one claims 1-9 as an ultrasound contrast agent.
Citation Information
Patent Citations
Gas-filled microvesicles with targeting ligand in respect of FC-region of an antibody or therapeutic agent
WO2008075191A2
A method for increasing product stability with hydrophobin variants
WO2015082772A1
HFB Bubbles
WO2017025826A1
